[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335380-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335380-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-effects-of-kras-mutations-on-the-prognosis-of-rectal-cancer-following-neoadjuvant-chemoradiotherapy-and-surgery","The Effects of KRAS Mutations on the Prognosis of Rectal Cancer Following Neoadjuvant Chemoradiotherapy and Surgery","","Background: KRAS gene mutations in rectal cancer are linked to worse outcomes, especially variants at codon 12. This study evaluated whether KRAS mutations serve as adverse prognostic factors after neoadjuvant concurrent chemoradiotherapy (CRT) and surgery. Methods: In 125 patients with cT2-4N0-2M0 rectal cancer treated between 2014 and 2023, the impact of KRAS status on disease-free survival (DFS) and locoregional recurrence-free survival (LRFS) was analyzed. Results: KRAS mutations were present in 20.0% overall, with 17.6% harboring codon 12 variants. DFS and LRFS were significantly reduced with KRAS mutations, with particularly low outcomes for codon 12. Pathologic complete response and overall survival were not associated with KRAS status.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-effects-of-kras-mutations-on-the-prognosis-of-rectal-cancer-following-neoadjuvant-chemoradiotherapy-and-surgery/335380/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-effects-of-kras-mutations-on-the-prognosis-of-rectal-cancer-following-neoadjuvant-chemoradiotherapy-and-surgery/335380.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What prognostic impact do KRAS mutations have after neoadjuvant chemoradiotherapy and surgery?","Question",{"text":63,"@type":64},"KRAS mutations are associated with decreased disease-free survival (DFS) and locoregional recurrence-free survival (LRFS). The study reports significant reductions compared with KRAS wild-type cases.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Are KRAS codon 12 variants more harmful than other KRAS mutations?",{"text":68,"@type":64},"Yes. DFS and LRFS are particularly low in the subgroup with KRAS mutations at codon 12, with statistically significant results.",{"name":70,"@type":61,"acceptedAnswer":71},"Do KRAS mutations affect pathologic complete response rate or overall survival?",{"text":72,"@type":64},"No. The pathologic complete response rate following CRT is not affected by KRAS mutations, and overall survival is not significantly associated with KRAS status in this study.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335380,1790012696,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","RESEARCH ARTICLE  \nEditorial Process: Submission:01/03/2024 Acceptance:07/13/2024  \nThe effects of KRAS Mutations on the Prognosis of Rectal Cancer Following Neoadjuvant Chemoradiotherapy and Surgery  \nJi Sun Park1, Soon Seong Lee1, Yoon Sun Choi2 *  \nAbstract  \nBackground: Rectal cancers with mutations in the KRAS gene have worse prognoses than wild-type malignancies. Variants at codon 12 ofKRAS have particularly detrimental effects on prognosis. We aimed to analyze whether KRAS mutations act as adverse prognostic factors following neoadjuvant concurrent chemoradiotherapy (CRT) and surgery for rectal cancer treatment. Methods: We analyzed the effects ofKRAS mutations on disease-free survival (DFS) and locoregional recurrence-free survival (LRFS) in 125 patients with cT2-4N0-2M0 rectal cancer who underwent surgery following CRT between June 2014 and March 2023 Inje University Busan Paik Hospital. Results: The median followup period was 39.7 (range, 7.5–98.2) months. There were 25 patients (20.0%) who harbored KRAS mutations. Among them, 22 patients (17.6%) had codon 12 variants. Overall, 43 patients (34.4%) showed recurrence, of which 10 (8.0%) had locoregional recurrence and 35 (28.0%) had distant metastases (two occurred simultaneously). DFS was significantly reduced in the patients with KRAS mutations (p = 0.005). LRFS was also reduced inpatients with KRAS mutations (p = 0.039). DFS and LRFS were also relatively low in the subgroup with KRAS mutations at codon 12 (n = 22) (p = 0.003 and p = 0.017, respectively) . However, pathologic complete response rate following CRT was not affected by KRAS mutations (p = 0.197) . Overall survival was also not associated with KRAS mutations (p = 0.486).Conclusion: KRAS mutation is related to decreased DFS and LRFS, when surgery is performed following neoadjuvant CRT to treat rectal cancer. These effects are particularly pronounced for KRAS mutations at codon 12.  \nKeywords: Rectal cancer-KRAS mutation-chemoradiotherapy-clinical oncology  \nAsian Pac J Cancer Prev, 25 (7), 2337-2342  \nIntroduction  \nMutations in the KRAS gene are common in colorectal cancer (CRC) . KRAS gene mutations occur in 17–25% of all cancers [1] . In patients with CRC who have KRAS gene mutations, the KRAS protein continuously stimulates downstream signaling to induce cell proliferation and survival, thereby resulting in a high risk of tumor formation and subsequent deterioration. KRAS mutations are associated with relatively fast relapse [2] and poor prognosis [3, 4] . A meta-analysis reported that KRAS mutations were not related to the efficacy of neoadjuvant chemoradiotherapy (CRT) [5] . However, according to another recent meta-analysis, KRAS mutations are associated with poor disease-free survival (DFS) in CRC [6] .  \nHotspots for KRAS mutations include codons 12, 13, and 61 [7]. Among these, mutations at codon 12 account for more than half of the known KRAS mutation subtypes [7]. In particular, in a Japanese multicenter study, patients  \nwith metastatic CRC who harbored KRAS mutations incodon 12 were found to have poorer treatment outcomes than those without the mutations [8] . Patients with KRAS mutations at G12C had the worst progression-free and overall survival (OS) rates [8] .  \nTreatment methods for rectal cancer vary depending on the location, size, and degree of tumor spread. Surgery, radiation therapy, and chemotherapy can all be used, depending on when the tumor is discovered. Early-stage CRC can be treated using endoscopic resection alone. Radiotherapy is administered for locally advanced CRC, most often in combination with chemotherapy prior to surgery. Combined CRT enhances treatment effectiveness and reduces the recurrence rate. Radical resection with pelvic lymph node dissection following neoadjuvant CRT is effective for lowering the recurrence rate in the pelvis and therefore, is currently the standard treatment for locally advanced CRC.  \nThis study aimed to analyze the impact of KRAS mutation","cbCaip1mxjvimWSl","https://ap.wps.com/l/cbCaip1mxjvimWSl","pdf",536206,"English","# Abstract\n# Introduction\n# Materials and Methods\n# Results\n# Discussion and Conclusion","[{\"question\":\"What prognostic impact do KRAS mutations have after neoadjuvant chemoradiotherapy and surgery?\",\"answer\":\"KRAS mutations are associated with decreased disease-free survival (DFS) and locoregional recurrence-free survival (LRFS). The study reports significant reductions compared with KRAS wild-type cases.\"},{\"question\":\"Are KRAS codon 12 variants more harmful than other KRAS mutations?\",\"answer\":\"Yes. DFS and LRFS are particularly low in the subgroup with KRAS mutations at codon 12, with statistically significant results.\"},{\"question\":\"Do KRAS mutations affect pathologic complete response rate or overall survival?\",\"answer\":\"No. The pathologic complete response rate following CRT is not affected by KRAS mutations, and overall survival is not significantly associated with KRAS status in this study.\"}]","The Effects of KRAS Mutations on the Prognosis of Rectal Cancer Following Neoadjuvant Chemoradiotherapy and Surgery | PDF",1790010755,15]